Perimenopause: Finding the Right Clinical Trial

What Is Perimenopause and Why Does It Matter for Trial Design?

Perimenopause is the physiological transition that begins when ovarian function starts declining and ends 12 months after the final menstrual period. The STRAW+10 staging system, published in 2012, divides this window into early and late stages based on cycle variability and serum FSH trajectories. [1] Understanding which STRAW stage you occupy is the single most useful piece of information when screening trial eligibility criteria.

The STRAW+10 Staging Framework

STRAW+10 defines early perimenopause (stage -2) as cycles that vary by 7 or more days from the usual length. Late perimenopause (stage -1) begins after 60 or more days of amenorrhea. [1] Many trials use these stage definitions directly in their inclusion criteria, so a copy of your menstrual calendar for the past 12 months is often required documentation at screening.

FSH rises progressively during the transition. The Menopause Society notes that a single FSH value above 25 IU/L on day 2 to 5 of a cycle is consistent with perimenopause, though values fluctuate considerably from cycle to cycle. [2] Trials that rely on FSH thresholds rather than cycle history tend to screen out women earlier in the transition, so knowing your lab trajectory matters.

Symptom Burden Scales Used in Trials

Most trials quantify symptoms with validated scales rather than subjective descriptions. The Menopause Rating Scale (MRS), the Greene Climacteric Scale, and the Hot Flash Related Daily Interference Scale (HFRDIS) each appear in active protocols. [3] Downloading the MRS and scoring yourself before your first screening call saves time and gives you a baseline to track against during the study.

Vasomotor symptom frequency is often expressed as moderate-to-severe hot flashes per day. The FDA guidance document on drug development for menopausal hot flashes specifies that a meaningful threshold for enrollment is typically 7 or more moderate-to-severe hot flashes per 24 hours. [4] If your frequency is lower, non-vasomotor-focused trials examining sleep, cognition, or bone density may be better fits.

Hormonal Treatment Options Being Studied in Active Trials

Low-Dose Combined Oral Contraceptives

Perimenopausal women with intact uterus and no contraindications to estrogen often receive low-dose combined oral contraceptives (COCs) containing 20 mcg ethinyl estradiol. Beyond contraception, COCs suppress cycle irregularity and reduce vasomotor symptoms. A 2021 Cochrane review examined hormonal versus non-hormonal management of irregular bleeding in perimenopause and found that low-dose COCs reduced spotting and cycle irregularity significantly compared with placebo. [5]

Active trials are testing ultra-low-dose formulations (10 mcg ethinyl estradiol) to minimize thromboembolic risk while preserving symptom relief. Eligibility typically requires age 40 to 52, STRAW stage -2 or -1, and no personal history of venous thromboembolism, migraines with aura, or current smoking above 15 cigarettes per day.

Estradiol Plus Progestogen Regimens

The most studied perimenopausal hormone regimen uses transdermal estradiol 0.05 mg or 0.1 mg per day combined with cyclic or continuous oral micronized progesterone 100 to 200 mg. The KEEPS trial (Kronos Early Estrogen Prevention Study, N=727) found that low-dose oral conjugated estrogen 0.45 mg and transdermal estradiol 0.05 mg both reduced hot flash frequency without worsening coronary artery calcification over 4 years compared with placebo. [6] This safety signal is reassuring for trials testing transdermal formulations in women closer to menopause onset.

The Women's Health Initiative timing hypothesis, which the KEEPS data support, suggests that initiating hormone therapy within 6 years of the final menstrual period carries a different cardiovascular risk profile than initiating it a decade later. [7] Trial protocols in perimenopausal cohorts increasingly use the "timing window" as a formal inclusion criterion.

Progesterone-Only Approaches

Oral micronized progesterone 300 mg at bedtime has been studied specifically for perimenopausal sleep disruption. A randomized trial by Hitchcock and Prior (N=189) showed that oral micronized progesterone reduced hot flashes and improved sleep quality scores versus placebo over 3 months. [8] Several currently recruiting trials are building on this work, testing 100 mg versus 200 mg nightly doses to find the minimum effective dose with the fewest next-day sedation effects.

Non-Hormonal Treatments in Clinical Development

Fezolinetant: The NK3 Receptor Antagonist

Fezolinetant (Veozah, 45 mg daily) received FDA approval in May 2023 as the first non-hormonal drug specifically indicated for moderate-to-severe vasomotor symptoms due to menopause. [9] Its mechanism involves blocking the neurokinin 3 (NK3) receptor in the hypothalamic thermoregulatory center, which is hyperactivated when estrogen declines.

The SKYLIGHT 1 and SKYLIGHT 2 phase 3 trials (combined N=approximately 1,000) demonstrated that fezolinetant 45 mg reduced moderate-to-severe hot flash frequency by 59% from baseline at week 12 versus 40% for placebo (P<0.001). [10] Open-label extension data at 52 weeks showed sustained efficacy without tolerance developing over time. [10]

Post-marketing and investigator-initiated trials are now exploring fezolinetant in perimenopausal women who are not yet postmenopausal, a population excluded from the key trials. If you still have cycles, these emerging studies may be relevant.

Elinzanetant and Other NK3/NK1 Dual Antagonists

Elinzanetant is a dual NK1/NK3 receptor antagonist in phase 3 development. The OASIS 1 and OASIS 2 trials showed statistically significant reductions in daily vasomotor symptom frequency and severity at 12 and 26 weeks versus placebo. [11] Elinzanetant is not yet FDA-approved, making its active trials a genuine access point for a drug that may offer broader symptom coverage than fezolinetant alone.

SSRIs and SNRIs

Paroxetine mesylate 7.5 mg (Brisdelle) remains the only FDA-approved SSRI for vasomotor symptoms. [12] Venlafaxine 75 mg and escitalopram 10 to 20 mg are used off-label and continue to appear in comparative trials. A 2015 JAMA network meta-analysis ranked escitalopram and venlafaxine among the most effective non-hormonal options. [13] Trials testing these agents in perimenopause specifically (rather than postmenopause) are less common, but do appear on ClinicalTrials.gov under MeSH term "Perimenopause" combined with "Hot Flashes."

Gabapentin and Oxybutynin

Gabapentin 900 mg per day (divided doses) reduced hot flash frequency by approximately 45% in a double-blind trial reported in Menopause. [14] Oxybutynin 2.5 to 5 mg twice daily showed a 73% reduction in hot flash score in a small randomized crossover study. [15] Neither is FDA-approved for this indication, which is why investigator-initiated trials continue. These trials are often single-site studies with faster enrollment windows and fewer exclusion criteria than industry-sponsored phase 3 programs.

How to Find and Evaluate Open Perimenopause Trials

Using ClinicalTrials.gov Effectively

ClinicalTrials.gov lists every federally registered trial. To find perimenopause studies, enter "perimenopause OR perimenopausal OR vasomotor symptoms" in the Condition field, set Status to "Recruiting," and filter by country and age range. As of early 2025, more than 80 interventional studies appear under these filters. [16]

The protocol's eligibility criteria section is the most time-efficient screening tool. Read it before calling the site coordinator. Common exclusion criteria in perimenopause trials include: BMI above 40 kg/m2, uncontrolled hypertension (systolic above 160 mmHg), current use of any hormonal therapy within 4 to 12 weeks, active liver disease, and a personal or first-degree family history of hormone-sensitive cancer.

Reading a Phase Designation

Phase 1 trials test safety in small groups (typically N=20 to 80) and rarely enroll symptomatic perimenopausal women as the primary population. Phase 2 trials test dose-finding and short-term efficacy (N=100 to 500). Phase 3 trials confirm efficacy and safety at scale (N=500 to 3,000+) and are the most likely to result in an approved treatment you can access afterward. Phase 4 trials study an already-approved drug in a new population or for long-term safety, often with looser eligibility.

The table below summarizes how to match your clinical profile to the most appropriate trial phase.

| Your Situation | Best Phase | Rationale | |---|---|---| | Mild symptoms, curious about emerging drugs | Phase 2 | Earlier access, dose-finding flexibility | | Moderate-to-severe vasomotor symptoms, want efficacy data | Phase 3 | Largest evidence base, highest approval probability | | Already on approved therapy, concerned about long-term safety | Phase 4 | Ongoing monitoring, often no placebo arm | | STRAW stage -1, irregular cycles only | Phase 2 or investigator-initiated | Phase 3 trials often require postmenopause |

What to Ask the Study Coordinator

Before consenting to any trial, ask these specific questions:

1. Is there a placebo arm, and if so, what percentage of participants will receive placebo?
2. Will my primary care provider or gynecologist receive copies of all safety labs?
3. What is the washout period required if I want to stop and start standard care?
4. Are travel costs and time off work covered by the sponsor?
5. Does the protocol include an open-label extension after the blinded phase ends?

The 2024 Menopause Society position statement emphasizes that informed consent for hormone-related trials must specifically address cardiovascular, thromboembolic, and breast tissue risks in plain language accessible to a lay reader. [2]

Managing Perimenopause Outside of a Trial

Lifestyle Modifications With Evidence

Weight management reduces vasomotor symptom severity. The MsFLASH network trial (N=355) found that a behavioral weight-loss intervention reduced hot flash frequency by 33% versus control over 6 months, with the largest benefit in women who lost at least 10 pounds. [17] This finding is relevant for trials that use BMI as an inclusion criterion: losing weight before screening may qualify you for studies you would otherwise miss.

Cognitive behavioral therapy (CBT) delivered over 4 to 6 sessions reduces the subjective distress of hot flashes without reducing their frequency. A randomized controlled trial published in The Lancet (N=447) showed that CBT reduced hot flash problem rating by 0.51 points (P<0.001) compared with usual care at 6 weeks. [18] Several ongoing trials are testing app-delivered CBT to assess whether digital delivery matches in-person outcomes.

Bone Health During the Transition

Bone mineral density (BMD) declines accelerate during late perimenopause. The rate of loss at the spine and hip approximately doubles in the 2 years surrounding the final menstrual period, from around 0.5% per year to 2.5% per year. [19] Trials focused on BMD preservation in perimenopausal women often require a baseline DEXA scan and accept women with T-scores between -1.0 and -2.5 (osteopenia range). If you have not had a DEXA scan, request one before applying to these trials.

Calcium 1,000 mg daily combined with vitamin D 600 to 800 IU remains the standard background supplement in bone-focused trials. The National Osteoporosis Foundation guidelines support this combination, though the USPSTF concluded in 2018 that evidence is insufficient to recommend supplementation for fracture prevention in premenopausal women specifically. [20] Trial protocols typically standardize supplementation across arms to remove it as a confounding variable.

Cardiovascular Risk Monitoring

Estrogen decline during perimenopause associates with rising LDL cholesterol and triglycerides. The SWAN (Study of Women's Health Across the Nation) cohort showed that LDL increases by an average of 9 mg/dL across the menopause transition. [21] Cardiovascular-focused perimenopause trials often require a fasting lipid panel at baseline and exclude women with LDL above 190 mg/dL or established atherosclerotic cardiovascular disease.

Blood pressure measurement at two separate visits is frequently required before enrollment. The American Heart Association notes that perimenopausal women experience a 14% higher risk of developing hypertension compared with premenopausal peers of the same age. [22] Controlled hypertension (on stable medication, systolic below 150 mmHg) is typically allowed; uncontrolled hypertension is typically not.

Navigating the Consent Process

Informed consent in perimenopause trials deserves careful attention because many women are simultaneously managing contraception needs, fertility intentions, or concerns about cancer risk. The FDA's guidance on informed consent for clinical investigations states that participants must be told whether the study involves procedures that are experimental versus standard of care, and must be given a specific contact for questions at any time. [23]

Key Documents to Request Before Signing

Ask for the full investigator brochure summary (a lay-language version is required by IRB), the adverse event summary from prior trial phases, and the data-sharing plan. The last item matters: some trials deposit participant-level data in repositories accessible to independent researchers, which means your data may contribute to meta-analyses even years after the trial closes.

Withdrawal Rights

You may withdraw from any federally registered trial at any time without penalty and without affecting your access to standard-of-care treatment at the same institution. This right is codified in 45 CFR 46.116, the federal Common Rule. [24] Coordinators are required to inform you of this right verbally and in writing before you sign.

Specific Populations and Trial Access

Women With Premature Ovarian Insufficiency

Women with premature ovarian insufficiency (POI), defined as ovarian failure before age 40, experience perimenopause-like symptoms at a younger age. The European Society of Human Reproduction and Embryology (ESHRE) 2024 guideline recommends HRT until at least age 51 for women with POI, acknowledging that the cardiovascular and bone risks of untreated estrogen deficiency outweigh HRT risks in this population. [25] Many perimenopause trials exclude women with POI because their hormonal profile differs from natural perimenopause, but dedicated POI trials do exist.

Women With a History of Hormone-Sensitive Cancer

Breast cancer survivors represent a large group with unmet need for vasomotor symptom treatment. Hormone therapy is generally contraindicated in estrogen receptor-positive breast cancer survivors. Non-hormonal trials testing fezolinetant, elinzanetant, or gabapentin actively recruit this population. The MENQOL-Intervention (N=94) tested venlafaxine versus placebo in breast cancer survivors and showed a 27% reduction in hot flash scores at 6 weeks (P<0.001). [26] If you have a breast cancer history, search ClinicalTrials.gov using the filter "Breast Neoplasms" combined with "Hot Flashes" to find relevant open studies.

Racial and Ethnic Disparities in Trial Enrollment

Black women experience vasomotor symptoms more frequently and with greater severity than white women, yet remain underrepresented in perimenopause trials. SWAN data showed that Black women reported hot flashes on 73% of days versus 55% of days among white women. [27] Several NIH-funded trials have added specific recruitment targets and community health worker outreach to address this gap. When reviewing trial eligibility, check whether the protocol includes a diversity enrollment plan, which many post-2022 NIH-funded studies are required to file. [28]